IGF1 induces cell proliferation in human pituitary tumors - Functional blockade of IGF1 receptor as a novel therapeutic approach in non-functioning tumors

Molecular and Cellular Endocrinology

Volumn 390, Issue 1-2, 2014, Pages 93-101

  Rubinfeld, Hadara ^a   Kammer, Adi ^a   Cohen, Ortal ^a   Gorshtein, Alexander ^a   Cohen, Zvi R ^a,b   Hadani, Moshe ^a,b   Werner, Haim ^a   Shimon, Ilan ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b SHEBA MEDICAL CENTER   (Israel)

Author keywords

IGF1; IGF1 receptor; IGF1 receptor inhibitor; Pituitary adenomas

Indexed keywords

CYCLIN D1; CYCLIN D3; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; ANTINEOPLASTIC AGENT; CCND1 PROTEIN, HUMAN; CCND3 PROTEIN, HUMAN; IGF1 PROTEIN, HUMAN; NVP-AEW541; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE;

ADULT; AGED; ANIMAL CELL; ARTICLE; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CELL VIABILITY; ENZYME PHOSPHORYLATION; FEMALE; HUMAN; HUMAN CELL; HYPOPHYSIS TUMOR; MALE; MIDDLE AGED; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; SIGNAL TRANSDUCTION; VERY ELDERLY; ADENOMA; ANIMAL; CELL CYCLE; DRUG EFFECTS; METABOLISM; PATHOLOGY; PHYSIOLOGY; PITUITARY NEOPLASMS; PROTEIN PROCESSING; TUMOR CELL LINE;

ADENOMA; ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ANTINEOPLASTIC AGENTS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN D1; CYCLIN D3; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; PITUITARY NEOPLASMS; PROTEIN PROCESSING, POST-TRANSLATIONAL; PYRIMIDINES; PYRROLES; RATS;

EID: 84899875739     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2014.04.007     Document Type: Article

References (53)

1. Alberti V.N., Takita L.C., de Mesquita M.I., Percario S., Maciel R.M. Immunohistochemical demonstration of insulin-like growth factor I (IGF-1) in normal and pathological human pituitary glands. Pathol. Res. Pract. 1991, 187:541-542.
2. Arnold J.R., Arnold D.F., Marland A., Karavitaki N., Wass J.A. GH replacement in patients with non-functioning pituitary adenoma (NFA) treated solely by surgery is not associated with increased risk of tumour recurrence. Clin. Endocrinol. (Oxf) 2009, 70:435-438.
3. Atkin S.L., Landolt A.M., Jeffreys R.V., Hipkin L., Radcliffe J., Squire C.R., White M.C. Differential effects of insulin-like growth factor 1 on the hormonal product and proliferation of glycoprotein-secreting human pituitary adenomas. J. Clin. Endocrinol. Metab. 1993, 77:1059-1066.
4. Atkin S.L., Landolt A.M., Foy P., Jeffreys R.V., Hipkin L., White M.C. Effects of insulin-like growth factor-I on growth hormone and prolactin secretion and cell proliferation of human somatotrophinomas and prolactinomas in vitro. Clin. Endocrinol. (Oxf) 1994, 41:503-509.
5. Bach M.A., Bondy C.A. Anatomy of the pituitary insulin-like growth factor system. Endocrinology 1992, 131:2588-2594.
6. Baserga R. The contradictions of the insulin-like growth factor 1 receptor. Oncogene 2000, 19:5574-5581.
7. Baserga R., Peruzzi F., Reiss K. The IGF-1 receptor in cancer biology. Int. J. Cancer 2003, 107:873-877.
8. Beuschlein F., Hancke K., Petrick M., Gobel H., Honegger J., Reincke M. Growth hormone receptor mRNA expression in non-functioning and somatotroph pituitary adenomas: implications for growth hormone substitution therapy?. Exp. Clin. Endocrinol. Diabetes 2005, 113:214-218.
9. Binnerts A., Uitterlinden P., Hofland L.J., van Koetsveld P., Lamberts S.W. The in vitro and in vivo effects of human growth hormone administration on tumor growth of rats bearing a transplantable rat pituitary tumor (7315b). Eur. J. Cancer 1990, 26:269-276.
10. Buchfelder M., Kann P.H., Wuster C., Tuschy U., Saller B., Brabant G., Kleindienst A., Nomikos P. Influence of GH substitution therapy in deficient adults on the recurrence rate of hormonally inactive pituitary adenomas: a case control study. Eur. J. Endocrinol. 2007, 157:149-156.
11. Buck E., Eyzaguirre A., Rosenfeld-Franklin M., Thomson S., Mulvihill M., Barr S., Brown E., O'Connor M., Yao Y., Pachter J., Miglarese M., Epstein D., Iwata K.K., Haley J.D., Gibson N.W., Ji Q.S. Feedback mechanisms promote cooperativity for small molecule inhibitors of epidermal and insulin-like growth factor receptors. Cancer Res. 2008, 68:8322-8332.
12. Cerovac V., Monteserin-Garcia J., Rubinfeld H., Buchfelder M., Losa M., Florio T., Paez-Pereda M., Stalla G.K., Theodoropoulou M. The somatostatin analogue octreotide confers sensitivity to rapamycin treatment on pituitary tumor cells. Cancer Res. 2010, 70:666-674.
13. Chung T.T., Evanson J., Walker D., Akker S.A., Besser G.M., Monson J.P., Grossman A.B., Drake W.M. Safety of GH replacement in hypopituitary patients with nonirradiated pituitary and peripituitary tumours. Clin. Endocrinol. (Oxf) 2008, 68:965-969.
14. Clausen L.R., Kristiansen M.T., Rasmussen L.M., Billestrup N., Blaabjerg O., Ledet T., Jorgensen J.O. Growth hormone receptor expression and function in pituitary adenomas. Clin. Endocrinol. (Oxf) 2004, 60:576-583.
15. Desbois-Mouthon C., Baron A., Blivet-Van Eggelpoel M.J., Fartoux L., Venot C., Bladt F., Housset C., Rosmorduc O. Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling pathway: rational basis for cotargeting insulin-like growth factor-1 receptor and epidermal growth factor receptor in hepatocellular carcinoma. Clin. Cancer Res. 2009, 15:5445-5456.
16. Fernandez M., Sanchez-Franco F., Palacios N., Sanchez I., Fernandez C., Cacicedo L. IGF-I inhibits apoptosis through the activation of the phosphatidylinositol 3-kinase/Akt pathway in pituitary cells. J. Mol. Endocrinol. 2004, 33:155-163.
17. Frajese G., Drake W.M., Loureiro R.A., Evanson J., Coyte D., Wood D.F., Grossman A.B., Besser G.M., Monson J.P. Hypothalamo-pituitary surveillance imaging in hypopituitary patients receiving long-term GH replacement therapy. J. Clin. Endocrinol. Metab. 2001, 86:5172-5175.
18. Gaillard R.C., Mattsson A.F., Akerblad A.C., Bengtsson B.A., Cara J., Feldt-Rasmussen U., Koltowska-Haggstrom M., Monson J.P., Saller B., Wilton P., Abs R. Overall and cause-specific mortality in GH-deficient adults on GH replacement. Eur. J. Endocrinol. 2012, 166:1069-1077.
19. Gallagher E.J., LeRoith D. The proliferating role of insulin and insulin-like growth factors in cancer. Trends Endocrinol. Metab. 2010, 21:610-618.
20. Garcia-Echeverria C., Pearson M.A., Marti A., Meyer T., Mestan J., Zimmermann J., Gao J., Brueggen J., Capraro H.G., Cozens R., Evans D.B., Fabbro D., Furet P., Porta D.G., Liebetanz J., Martiny-Baron G., Ruetz S., Hofmann F. In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase. Cancer Cell 2004, 5:231-239.
21. Goodyer C.G., De Stephano L., Lai W.H., Guyda H.J., Posner B.I. Characterization of insulin-like growth factor receptors in rat anterior pituitary, hypothalamus, and brain. Endocrinology 1984, 114:1187-1195.
22. Gorshtein A., Rubinfeld H., Kendler E., Theodoropoulou M., Cerovac V., Stalla G.K., Cohen Z.R., Hadani M., Shimon I. Mammalian target of rapamycin inhibitors rapamycin and RAD001 (everolimus) induce anti-proliferative effects in GH-secreting pituitary tumor cells in vitro. Endocr. Relat. Cancer 2009, 16:1017-1027.
23. Guevara-Aguirre J., Balasubramanian P., Guevara-Aguirre M., Wei M., Madia F., Cheng C.W., Hwang D., Martin-Montalvo A., Saavedra J., Ingles S., de Cabo R., Cohen P., Longo V.D. Growth hormone receptor deficiency is associated with a major reduction in pro-aging signaling, cancer, and diabetes in humans. Sci. Transl. Med. 2011, 3:70ra13.
24. Haisa M. The type 1 insulin-like growth factor receptor signalling system and targeted tyrosine kinase inhibition in cancer. J. Int. Med. Res. 2013, 41:253-264.
25. Hatrick A.G., Boghalo P., Bingham J.B., Ayres A.B., Sonksen P.H., Russell-Jones D.L. Does GH replacement therapy in adult GH-deficient patients result in recurrence or increase in size of pituitary tumours?. Eur. J. Endocrinol. 2002, 146:807-811.
26. Hibberts N.A., Simpson D.J., Bicknell J.E., Broome J.C., Hoban P.R., Clayton R.N., Farrell W.E. Analysis of cyclin D1 (CCND1) allelic imbalance and overexpression in sporadic human pituitary tumors. Clin. Cancer Res. 1999, 5:2133-2139.
27. Huang F., Greer A., Hurlburt W., Han X., Hafezi R., Wittenberg G.M., Reeves K., Chen J., Robinson D., Li A., Lee F.Y., Gottardis M.M., Clark E., Helman L., Attar R.M., Dongre A., Carboni J.M. The mechanisms of differential sensitivity to an insulin-like growth factor-1 receptor inhibitor (BMS-536924) and rationale for combining with EGFR/HER2 inhibitors. Cancer Res. 2009, 69:161-170.
28. Jordan S., Lidhar K., Korbonits M., Lowe D.G., Grossman A.B. Cyclin D and cyclin E expression in normal and adenomatous pituitary. Eur. J. Endocrinol. 2000, 143:R1-R6.
29. Kola B., Korbonits M., Diaz-Cano S., Kaltsas G., Morris D.G., Jordan S., Metherell L., Powell M., Czirjak S., Arnaldi G., Bustin S., Boscaro M., Mantero F., Grossman A.B. Reduced expression of the growth hormone and type 1 insulin-like growth factor receptors in human somatotroph tumours and an analysis of possible mutations of the growth hormone receptor. Clin. Endocrinol. (Oxf) 2003, 59:328-338.
30. Lee M., Theodoropoulou M., Graw J., Roncaroli F., Zatelli M.C., Pellegata N.S. Levels of p27 sensitize to dual PI3K/mTOR inhibition. Mol. Cancer Ther. 2011, 10:1450-1459.
31. McCaffrey T.A., Agarwal L.A., Weksler B.B. A rapid fluorometric DNA assay for the measurement of cell density and proliferation in vitro. In Vitro Cell. Dev. Biol. 1988, 24:247-252.
32. Metzger A.K., Mohapatra G., Minn Y.A., Bollen A.W., Lamborn K., Waldman F.M., Wilson C.B., Feuerstein B.G. Multiple genetic aberrations including evidence of chromosome 11q13 rearrangement detected in pituitary adenomas by comparative genomic hybridization. J. Neurosurg. 1999, 90:306-314.
33. Morita S., Yamashita S., Melmed S. Insulin-like growth factor I action on rat anterior pituitary cells: effects of intracellular messengers on growth hormone secretion and messenger ribonucleic acid levels. Endocrinology 1987, 121:2000-2006.
34. Niiori-Onishi A., Iwasaki Y., Mutsuga N., Oiso Y., Inoue K., Saito H. Molecular mechanisms of the negative effect of insulin-like growth factor-I on growth hormone gene expression in MtT/S somatotroph cells. Endocrinology 1999, 140:344-349.
35. Nolting S., Garcia E., Alusi G., Giubellino A., Pacak K., Korbonits M., Grossman A.B. Combined blockade of signalling pathways shows marked anti-tumour potential in phaeochromocytoma cell lines. J. Mol. Endocrinol. 2012, 49:79-96.
36. Olmos D., Postel-Vinay S., Molife L.R., Okuno S.H., Schuetze S.M., Paccagnella M.L., Batzel G.N., Yin D., Pritchard-Jones K., Judson I., Worden F.P., Gualberto A., Scurr M., de Bono J.S., Haluska P. Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study. Lancet Oncol. 2010, 11:129-135.
37. Olsson D.S., Buchfelder M., Schlaffer S., Bengtsson B.A., Jakobsson K.E., Johannsson G., Nilsson A.G. Comparing progression of non-functioning pituitary adenomas in hypopituitarism patients with and without long-term GH replacement therapy. Eur. J. Endocrinol. 2009, 161:663-669.
38. Oomizu S., Takeuchi S., Takahashi S. Stimulatory effect of insulin-like growth factor I on proliferation of mouse pituitary cells in serum-free culture. J. Endocrinol. 1998, 157:53-62.
39. Otsuka F., Tamiya T., Yamauchi T., Ogura T., Ohmoto T., Makino H. Quantitative analysis of growth-related factors in human pituitary adenomas: lowered insulin-like growth factor-I and its receptor mRNA in growth hormone-producing adenomas. Regul. Pept. 1999, 83:31-38.
40. Rose A., Froment P., Perrot V., Quon M.J., LeRoith D., Dupont J. The luteinizing hormone-releasing hormone inhibits the anti-apoptotic activity of insulin-like growth factor-1 in pituitary alphaT3 cells by protein kinase calpha-mediated negative regulation of Akt. J. Biol. Chem. 2004, 279:52500-52516.
41. Rubinfeld H., Hadani M., Barkai G., Taylor J.E., Culler M.D., Shimon I. Cortistatin inhibits growth hormone release from human fetal and adenoma pituitary cells and prolactin secretion from cultured prolactinomas. J. Clin. Endocrinol. Metab. 2006, 91:2257-2263.
42. Ruscica M., Arvigo M., Gatto F., Dozio E., Feltrin D., Culler M.D., Minuto F., Motta M., Ferone D., Magni P. Regulation of prostate cancer cell proliferation by somatostatin receptor activation. Mol. Cell. Endocrinol. 2010, 315:254-262.
43. Samani A.A., Yakar S., LeRoith D., Brodt P. The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr. Rev. 2007, 28:20-47.
44. Shelton J.G., Steelman L.S., White E.R., McCubrey J.A. Synergy between PI3K/Akt and Raf/MEK/ERK pathways in IGF-1R mediated cell cycle progression and prevention of apoptosis in hematopoietic cells. Cell Cycle 2004, 3:372-379.
45. Simpson D.J., Frost S.J., Bicknell J.E., Broome J.C., McNicol A.M., Clayton R.N., Farrell W.E. Aberrant expression of G(1)/S regulators is a frequent event in sporadic pituitary adenomas. Carcinogenesis 2001, 22:1149-1154.
46. Steuerman R., Shevah O., Laron Z. Congenital IGF1 deficiency tends to confer protection against post-natal development of malignancies. Eur. J. Endocrinol. 2011, 164:485-489.
47. Turner H.E., Nagy Z., Sullivan N., Esiri M.M., Wass J.A. Expression analysis of cyclins in pituitary adenomas and the normal pituitary gland. Clin. Endocrinol. (Oxf) 2000, 53:337-344.
48. van Koetsveld P.M., Vitale G., de Herder W.W., Feelders R.A., van der Wansem K., Waaijers M., van Eijck C.H., Speel E.J., Croze E., van der Lely A.J., Lamberts S.W., Hofland L.J. Potent inhibitory effects of type I interferons on human adrenocortical carcinoma cell growth. J. Clin. Endocrinol. Metab. 2006, 91:4537-4543.
49. Vitale G., van Koetsveld P.M., de Herder W.W., van der Wansem K., Janssen J.A., Colao A., Lombardi G., Lamberts S.W., Hofland L.J. Effects of type I interferons on IGF-mediated autocrine/paracrine growth of human neuroendocrine tumor cells. Am. J. Physiol. Endocrinol. Metab. 2009, 296:E559-E566.
50. Wang Y., Sun Y. Insulin-like growth factor receptor-1 as an anti-cancer target: blocking transformation and inducing apoptosis. Curr. Cancer Drug Targets 2002, 2:191-207.
51. Werner H., LeRoith D. The role of the insulin-like growth factor system in human cancer. Adv. Cancer Res. 1996, 68:183-223.
52. Yamashita S., Weiss M., Melmed S. Insulin-like growth factor I regulates growth hormone secretion and messenger ribonucleic acid levels in human pituitary tumor cells. J. Clin. Endocrinol. Metab. 1986, 63:730-735.
53. Zatelli M.C., Minoia M., Filieri C., Tagliati F., Buratto M., Ambrosio M.R., Lapparelli M., Scanarini M., Degli Uberti E.C. Effect of everolimus on cell viability in nonfunctioning pituitary adenomas. J. Clin. Endocrinol. Metab. 2010, 95:968-976.